Free Trial
NASDAQ:TSVT

2seventy bio Q4 2024 Earnings Report

2seventy bio logo
$4.99 +0.01 (+0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$4.99 0.00 (-0.10%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

2seventy bio EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

2seventy bio Revenue Results

Actual Revenue
$2.93 million
Expected Revenue
$12.84 million
Beat/Miss
Missed by -$9.91 million
YoY Revenue Growth
N/A

2seventy bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
11:30AM ET

Upcoming Earnings

2seventy bio's Q1 2025 earnings is scheduled for Thursday, May 1, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

2seventy bio Earnings Headlines

2seventy bio (NASDAQ:TSVT) Earns "Sell (E+)" Rating from Weiss Ratings
Massive red flag about American consumer
Why is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U.S. dollar would crash for years. In 2025, it looks like it finally is. What does that mean for you money... and was this President Trump's plan all along? A widely followed 25-year economist and investor explains exactly what's happening, what could come next, and how to position your money on this page here.
2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More 2seventy bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 2seventy bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 2seventy bio and other key companies, straight to your email.

About 2seventy bio

2seventy bio (NASDAQ:TSVT), a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

View 2seventy bio Profile

More Earnings Resources from MarketBeat